BIOENGINEER

Virtual Tumors Point to New Drug Combinations for Hard-to-Treat Lung Cancer Mutations

A new quantitative systems pharmacology model spanning all three classes of BRAF-mutant lung cancer predicts that MEK-ERK ...
Medical Xpress

The role of fibronectin in BRAF-mutant thyroid cancer treatment

New research overseen by University of Colorado Cancer Center member Rebecca Schweppe, Ph.D., could lead to improved treatment for people with thyroid cancer characterized by a mutation in the BRAF ...
CURE

Ojemda Shrank Tumors in 43% of Patients With Rare BRAF, CRAF Changes

In a phase 2 study, Ojemda (tovorafenib) led to responses in 43% of adults with melanoma or other solid tumors that carried rare RAF gene changes. Ojemda (tovorafenib) shrank tumors in 10 of 23 adults ...
BIOENGINEER

How a Single Gene Loss Helps Melanoma Outsmart Targeted Drugs

Melanoma has long been one of oncology’s most instructive adversaries. Roughly half of all melanomas are driven by mutations ...
Business Wire

JS InnoPharm Initiates Treatment With JSI-1187, a Selective ERK Inhibitor, in Combination With Dabrafenib for Advanced Solid Tumors With BRAF V600E/K mutations

CHICAGO & SHANGHAI--(BUSINESS WIRE)--JS InnoPharm Ltd initiated the JSI-1187 plus dabrafenib combination dose-escalation phase of the Phase 1 study for patients with locally advanced or metastatic ...
ascopubs.org

The role of activating mutations of KRAS, BRAF, and PIK3CA pathway convergence at the transcriptional level and prediction of treatment response to cetuximab in colorectal cancer.

The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer. This is an ASCO Meeting Abstract from the 2011 ASCO Annual Meeting I. This abstract does ...

Nuvectis’ In-Licensed Cancer Drug Earned Breakthrough Designation in China, and It’s Not Even Their Lead Asset

Detailed price information for Nuvectis Pharma Inc (NVCT-Q) from The Globe and Mail including charting and trades.
MarketScreener

Nuvectis Pharma, Inc. Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade Glioma

Nuvectis Pharma, Inc. announced that NXP200 (HSK42360), an oral, brain-penetrant, paradox-breaker BRAF inhibitor, has been g (BTD) for the treatment of patients with BRAF V600-mutant, recurrent or ...